GLA
IBRX icon

Good Life Advisors’s ImmunityBio IBRX Stock Holding History

Good Life Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$151K Hold
57,311
– – 0.01% 486
2025
Q1 		$173K Buy
+57,311
New +$174K 0.01% 475

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Good Life Advisors's IBRX Position: Q2 2025 in Review

Good Life Advisors held its ImmunityBio (IBRX) position steady in Q2 2025 at 57,311 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #486.

Good Life Advisors first reported a position in IBRX in Q1 2025 and has held it in 2 quarters since. The position peaked at $173K in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Good Life Advisors held 57,311 shares of ImmunityBio worth $151K as of Q2 2025.
  • Good Life Advisors left its ImmunityBio share count unchanged in Q2 2025.
  • ImmunityBio made up 0.01% of Good Life Advisors's portfolio in Q2 2025, its #486 holding.
  • Good Life Advisors first reported a position in ImmunityBio in Q1 2025 and has held it in 2 quarters since.
  • Good Life Advisors's ImmunityBio position peaked at $173K in Q1 2025.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.